Search

Conozca los últimos avances en el tratamiento contra el cáncer pulmonar en MSK.

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.

Thanks to pioneering work done at MSK, a powerful new form of radiation therapy is changing the treatment of advanced cancers.

Positive results from a clinical trial published in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.

Diane Reidy-Lagunes sits down with Mary Elizabeth Williams to discuss what it was like being part of a phase 1 clinical trial, how clear communication can affect health outcomes, how guilt often accompanies survival, and what not to say to a cancer patient.

Data from 25,000 patients is helping scientists answer this and many other important questions.

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce that Selwyn M. Vickers, MD, FACS, President and Chief Executive Officer of MSK, and Andrea Schietinger, PhD, Associate Member of the Immunology Program at the Sloan Kettering Institute will be honored at the 2023 American Association for Cancer Research (AACR) Annual Meeting for their significant contributions to cancer research and care.

Learn how blood tests called liquid biopsies may be used to find, diagnose, and treat cancer anywhere in the body.